MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-23-2026
Arbutus Biopharma Corporation ROA Ratio 2011-2026 | ABUS
Annual ROA Ratio Arbutus Biopharma Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -35.41 | -53.09 | -50.45 | -35.54 | -37.29 | -46.5 | -145.66 | -25.04 | -35.59 | -139.23 | -8.58 | -32.86 | -19.61 | 56.93 | -71.02 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 56.93 | -145.66 | -45.26 |
Quarterly ROA Ratio Arbutus Biopharma Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -40.48 | -46.6 | -61.41 | -38.3 | -50.97 | -49.61 | -46.91 | -30.88 | -39.5 | -35.45 | -32.44 | -21.93 | -33.5 | -29.79 | -44.11 | -37.09 | -50.77 | -52.89 | -48.84 | -34.07 | -57.43 | -121.93 | -133.74 | -145.66 | -130.31 | -62.87 | -39.42 | -25.04 | -32.18 | -26.33 | -35.39 | -35.59 | -99.7 | -101.91 | -141.33 | -139.23 | -60.71 | -57.68 | -12.65 | -8.58 | -13.06 | -16.27 | -19.33 | -32.86 | -31.26 | -32.22 | -31.28 | -19.61 | -15.99 | -7.75 | -3.55 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -3.55 | -145.66 | -49.34 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
-27.33 | $ 8.48 | 6.0 % | $ 83.8 M |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
-31.06 | $ 3.66 | -1.48 % | $ 8.81 B |  Australia |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | France |
 |
Esperion Therapeutics
ESPR
|
-4.87 | $ 2.19 | 0.92 % | $ 455 M | USA |
 |
Evogene Ltd.
EVGN
|
-39.9 | $ 0.78 | -4.39 % | $ 27.9 M |  Israel |
 |
Applied Therapeutics
APLT
|
-218.41 | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Genmab A/S
GMAB
|
22.5 | $ 28.2 | -0.18 % | $ 18 B |  Danmark |
 |
Grifols, S.A.
GRFS
|
1.38 | $ 8.38 | 2.01 % | $ 6.83 B |  Spain |
 |
GT Biopharma
GTBP
|
-349.79 | $ 0.38 | 2.47 % | $ 2.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
6.02 | $ 21.28 | 4.44 % | $ 995 M | USA |
 |
Halozyme Therapeutics
HALO
|
12.55 | $ 66.92 | -1.33 % | $ 8.02 B | USA |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
12.48 | $ 29.05 | 0.55 % | $ 1.67 B | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
|
Immatics N.V.
IMTX
|
1.73 | $ 10.87 | 4.17 % | $ 684 M | Germany |
 |
Incyte Corporation
INCY
|
18.49 | $ 95.33 | -0.77 % | $ 18.6 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
-1.42 | $ 1.46 | 4.29 % | $ 375 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Allakos
ALLK
|
-76.23 | - | - | $ 28.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 2.99 | 2.4 % | $ 4.92 M | Israel |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
-52.23 | $ 4.2 | 2.82 % | $ 449 M | USA |
 |
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-3.73 | $ 24.24 | 0.1 % | $ 3.08 B | USA |
 |
Innate Pharma S.A.
IPHA
|
-19.74 | $ 1.47 | 4.26 % | $ 235 M | France |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
-44.38 | $ 32.59 | 1.09 % | $ 2.16 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
-48.81 | $ 1.48 | -0.67 % | $ 394 M | Britain |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
-79.06 | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
12.03 | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
0.11 | - | - | $ 96.9 B | Britain |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
-1008.51 | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
3.5 | - | 0.49 % | $ 251 B |  Cayman-islands |